Intersect ENT Inc (NASDAQ:XENT) Forecasted to Earn Q2 2019 Earnings of ($0.35) Per Share
Intersect ENT Inc (NASDAQ:XENT) – Svb Leerink dropped their Q2 2019 EPS estimates for Intersect ENT in a report released on Wednesday, July 10th. Svb Leerink analyst R. Newitter now forecasts that the medical equipment provider will post earnings of ($0.35) per share for the quarter, down from their previous forecast of ($0.33). Svb Leerink currently has a “Market Perform” rating and a $29.00 target price on the stock. Svb Leerink also issued estimates for Intersect ENT’s Q3 2019 earnings at ($0.41) EPS, Q4 2019 earnings at ($0.31) EPS, FY2019 earnings at ($1.41) EPS and FY2020 earnings at ($0.97) EPS.
Other equities analysts have also issued research reports about the stock. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 4th. Zacks Investment Research lowered shares of Inflarx from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Northland Securities raised shares of Akoustis Technologies from a “market perform” rating to an “outperform” rating in a report on Wednesday. Berenberg Bank reissued a “buy” rating and issued a GBX 620 ($8.10) price target on shares of in a report on Friday, June 21st. Finally, Leerink Swann lowered shares of Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 price target on the stock. in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $30.39.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Monday, May 6th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.05). The company had revenue of $26.70 million during the quarter, compared to the consensus estimate of $26.34 million. Intersect ENT had a negative return on equity of 22.90% and a negative net margin of 24.99%. Intersect ENT’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.21) EPS.
A number of institutional investors and hedge funds have recently made changes to their positions in XENT. FMR LLC boosted its position in Intersect ENT by 1,863.8% during the 1st quarter. FMR LLC now owns 632,451 shares of the medical equipment provider’s stock valued at $20,334,000 after buying an additional 600,246 shares during the period. William Blair Investment Management LLC boosted its position in Intersect ENT by 35.6% during the 1st quarter. William Blair Investment Management LLC now owns 528,404 shares of the medical equipment provider’s stock valued at $16,988,000 after buying an additional 138,780 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new stake in Intersect ENT during the 4th quarter valued at $3,382,000. Pura Vida Investments LLC boosted its position in Intersect ENT by 122.5% during the 4th quarter. Pura Vida Investments LLC now owns 190,335 shares of the medical equipment provider’s stock valued at $5,364,000 after buying an additional 104,808 shares during the period. Finally, Great Lakes Advisors LLC purchased a new stake in Intersect ENT during the 1st quarter valued at $3,154,000. 92.00% of the stock is owned by institutional investors and hedge funds.
In other news, insider Susan P. Stimson sold 2,663 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $30.00, for a total value of $79,890.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lisa D. Earnhardt sold 29,588 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $28.43, for a total transaction of $841,186.84. The disclosure for this sale can be found here. Insiders sold a total of 77,951 shares of company stock valued at $2,302,205 in the last ninety days. 5.90% of the stock is owned by corporate insiders.
About Intersect ENT
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.